News
September 17, 2025
DEBx Medical Receives COFEPRIS Market Approval in Mexico for DEBRICHEM®
DEBx Medical wins COFEPRIS approval for DEBRICHEM®. Mexico launch with Biotechlives set for AMCICHAC 2025 in León, advancing wound care nationwide.
**DEBx Medical Receives COFEPRIS Market Approval in Mexico for DEBRICHEM®**
DEBx Medical, a company dedicated to innovative wound care solutions, has announced it has received market approval from the Federal Commission for Protection against Sanitary Risk (COFEPRIS) in Mexico for its flagship product, DEBRICHEM®. This significant regulatory milestone paves the way for the introduction of DEBRICHEM® to the Mexican healthcare market, promising to improve treatment options for patients suffering from chronic and complex wounds.
DEBRICHEM® is a unique topical debridement agent designed to remove necrotic tissue and debris from wounds, promoting a cleaner wound bed and facilitating the natural healing process. Traditional methods of debridement can be time-consuming, painful, and sometimes require surgical intervention. DEBRICHEM® offers a non-surgical alternative, potentially reducing patient discomfort and healthcare costs.
The company is partnering with Biotechlives for the commercial launch of DEBRICHEM® in Mexico. Biotechlives, a company specializing in the distribution of innovative medical technologies, will be responsible for bringing DEBRICHEM® to healthcare professionals and patients across the country. The official launch is scheduled to coincide with the Annual Mexican Congress of Angiology, Vascular and Endovascular Surgery (AMCICHAC) in León in 2025. This strategic timing will allow DEBx Medical and Biotechlives to showcase DEBRICHEM® to a wide audience of specialists and key opinion leaders in the field of wound care.
The approval and subsequent launch of DEBRICHEM® in Mexico represent a significant step forward for DEBx Medical's mission to improve wound care globally. With the prevalence of chronic wounds on the rise due to factors such as diabetes and aging populations, the need for effective and accessible debridement solutions is greater than ever. DEBRICHEM® offers a promising solution for healthcare providers seeking to optimize wound management and improve patient outcomes. The company anticipates that DEBRICHEM® will become an integral part of wound care protocols throughout Mexico, contributing to better healing rates and improved quality of life for patients with challenging wounds.
DEBx Medical, a company dedicated to innovative wound care solutions, has announced it has received market approval from the Federal Commission for Protection against Sanitary Risk (COFEPRIS) in Mexico for its flagship product, DEBRICHEM®. This significant regulatory milestone paves the way for the introduction of DEBRICHEM® to the Mexican healthcare market, promising to improve treatment options for patients suffering from chronic and complex wounds.
DEBRICHEM® is a unique topical debridement agent designed to remove necrotic tissue and debris from wounds, promoting a cleaner wound bed and facilitating the natural healing process. Traditional methods of debridement can be time-consuming, painful, and sometimes require surgical intervention. DEBRICHEM® offers a non-surgical alternative, potentially reducing patient discomfort and healthcare costs.
The company is partnering with Biotechlives for the commercial launch of DEBRICHEM® in Mexico. Biotechlives, a company specializing in the distribution of innovative medical technologies, will be responsible for bringing DEBRICHEM® to healthcare professionals and patients across the country. The official launch is scheduled to coincide with the Annual Mexican Congress of Angiology, Vascular and Endovascular Surgery (AMCICHAC) in León in 2025. This strategic timing will allow DEBx Medical and Biotechlives to showcase DEBRICHEM® to a wide audience of specialists and key opinion leaders in the field of wound care.
The approval and subsequent launch of DEBRICHEM® in Mexico represent a significant step forward for DEBx Medical's mission to improve wound care globally. With the prevalence of chronic wounds on the rise due to factors such as diabetes and aging populations, the need for effective and accessible debridement solutions is greater than ever. DEBRICHEM® offers a promising solution for healthcare providers seeking to optimize wound management and improve patient outcomes. The company anticipates that DEBRICHEM® will become an integral part of wound care protocols throughout Mexico, contributing to better healing rates and improved quality of life for patients with challenging wounds.
Category:
Business